arrow
J

Jørgen Jahnsen

University of Oslo
H指数:55
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-TNF withdrawal or long-term treatment in ulcerative colitis (BIOSTOP): a multicentre open label, randomized controlled trial

抗肿瘤坏死因子撤药或长期治疗在溃疡性结肠炎中的应用(BIOSTOP):一项多中心开放标签随机对照试验

2026-08-060
PRE
High consumption of risk medication and underutilization of proton pump inhibitors among patients with upper gastrointestinal bleeding due to peptic ulcers and erosions (BLUE study)

高风险药物的高消费以及质子泵抑制剂在因消化性溃疡和糜烂引起的上消化道出血患者中的利用不足(BLUE研究)

2025-12-010
PRE
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

炎症性肠病患者通过1年维持治疗使用vedolizumab或皮下注射infliximab因疗效不足而停药的比例:一项系统文献综述和荟萃分析

2025-10-080
OA
Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

炎症性肠病期间SARS-CoV-2混合免疫力不足

2025-02-010
OAAI
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
2025-01-010
PRE
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
2024-10-011
OAAI
NEUTRALISING ANTIBODY RESPONSES TO BIVALENT SARS-CoV-2 VACCINES AND HYBRID IMMUNITY IN PATIENTS ONTNF INHIBITORS: A PROSPECTIVE COHORT STUDY

对接受抗TNF抑制剂治疗的患者接种双价SARS-CoV-2疫苗及混合免疫后的中和抗体反应:一项前瞻性队列研究

2024-06-010
PRE
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
2023-02-266
OA
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
2023-01-0121
OAAI
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
2022-10-0513
OAAI